Impact of Dyspnea, Regional Lung Ventilation, and Diaphragmatic Function During de Novo Acute Respiratory Failure
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 5, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to better manage acute respiratory failure, which is a serious condition where the lungs cannot get enough oxygen to the body. The trial aims to understand how patients feel short of breath (dyspnea), how well their lungs are working in different areas, and how their diaphragm (a muscle that helps us breathe) is functioning. By observing these factors, researchers hope to identify who is at risk of needing a breathing tube (intubation) and to improve treatments that help patients breathe without invasive methods.
To participate in this study, individuals must be over 18 years old and show signs of acute respiratory insufficiency, such as low oxygen levels and a fast breathing rate, while needing significant oxygen support. Patients who have certain chronic lung diseases, severe respiratory issues, or other specific health concerns may not be eligible. Those who join the trial can expect to undergo various assessments to monitor their breathing and lung function, helping doctors understand the best ways to support patients experiencing acute respiratory failure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18
- * Acute respiratory insufficiency defined by the three following items :
- • 1. PaO2/ FiO2 \<300
- • 2. Respiratory rate \> 25/min
- • 3. Oxygen support \> 10L/min or High Flow nasal oxygen (HFNO)
- • Non opposition by the patient to be included
- • Social insurance
- Exclusion Criteria:
- • Respiratory acidosis (pH \< 7,35 PaCO2 \> 45mmHg or 6kPa)
- • Chronic respiratory disease ( COPD, bronchiectasis...)
- • Cardiogenic Acute lung oedema
- • Non intubation decision at randomisation
- • Contraindication for Electro-impedance tomography-belt placement (chest trauma with rib fractures, thoracic wound, chest tube).
- • Uncommunicative patient (Glasgow coma scale \<12)
- • Guardianship or curators for vulnerable patients.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Martin DRES, MD PhD
Study Director
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials